Any feedback?
Please rate this page
(all_enzymes.php)
(0/150)

BRENDA support

3.4.23.B10: Rous sarcoma virus retropepsin

This is an abbreviated version!
For detailed information about Rous sarcoma virus retropepsin, go to the full flat file.

Word Map on EC 3.4.23.B10

Reaction

The cleavage sequence in the natural substrate NC-PR is PPAVS-/-LAMTMRR. The activity can be improved by substitution by Trp, Tyr, Phe, Leu, Arg, Glu, His or Ala in P1, Tyr in P3', and Arg, Phe, Asn or His in P3 =

Synonyms

AMV PR, AMV/RSV PR, avian myeloblastosis virus protease, avian myeloblastosis virus retropepsin, capsid protein P27, core protein P10, core protein P19, core protein P2A, core protein P2B, Gag polyprotein, Gag polyprotein p10 sequence, inner coat protein P12, More, p10-CA protease, p10-capsid protease, p15 protein, protease P15, Rous sarcoma virus protease, Rous sarcoma virus retropepsin, RSV PR, RSV protease, RSV/AMV retropepsin, viral protease

ECTree

     3 Hydrolases
         3.4 Acting on peptide bonds (peptidases)
             3.4.23 Aspartic endopeptidases
                3.4.23.B10 Rous sarcoma virus retropepsin

Engineering

Engineering on EC 3.4.23.B10 - Rous sarcoma virus retropepsin

Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
S38T/I42D/I44V/M73V/A100L/V104T/R105P/G106V/S107N
A100L
A40S
-
mutant enzyme shows 23% of the activity compared to wild-type enzyme with PPAVSLAMTMRR
A40T
-
mutant enzyme is inactive with PPAVSLAMTMRR
D37S
-
mutant enzyme is inactive with PPAVSLAMTMRR
DELTAN61-Q63
H65G
-
mutant enzyme is inactive with PPAVSLAMTMRR
H65G/R105P/G106V
-
mutant enzyme shows about 25% of the activity of the wild-type enzyme in RSV substrates, about 5fold higher activity with the HIV-1 peptide substrate PRKILFLDGRR
L180A/L184A/V187A
-
site-directed mutagenesis of the Gag polyprotein p10 sequence residues, the mutant protein shows normal nucleocytoplasmic trafficking and localization at the cell plasmamembrane and in the cytosol
L219A
-
site-directed mutagenesis of the Gag polyprotein p10 sequence residue leads to accumulation of the mutant protein in the nucleus and reduced virus assembly, overview
L229A
-
site-directed mutagenesis of the Gag polyprotein p10 sequence residue leads to accumulation of the mutant protein in the nucleus and reduced virus assembly, overview
M239F
-
site-directed mutagenesis of the p10-capsid protease sequence of Gag polyprotein does not affect the enzyme activity and virus replication
M239G
-
site-directed mutagenesis of the p10-capsid protease sequence of Gag polyprotein abolishes the enzyme activity and blocks Rous sarcoma virus replication, detrimental effect, overview
M73V/A100L
N61P/P62L/Q63M
-
mutant enzyme shows 434% of the activity with PPAVSLAMTMRR as substrate compared to activity of the wild-type enzyme
P240F
-
site-directed mutagenesis of the p10-capsid protease sequence of Gag polyprotein abolishes the enzyme activity and blocks Rous sarcoma virus replication, detrimental effect, overview
R105P/G106V
R105P/G106V/H65G
-
mutant enzyme exhibits behavior very similar to the wild-type enzyme for substitutions in the P4, P3, P2, P2', and P3' of the PPAVSLAMTMRR substrate positions. In contrast the mutants behave more like the HIV-1 protease in preference for amino acids substituted in the P1 and P1' positions
R105P/G106V/S107N
S107N
S38T
-
200% of the activity relative to wild-type enzyme with PPAVSLAMTMRR
S38T/I42D/I44V/M73V/A100L/L104T/R105P/G106V/S107N
-
the murtant enzyme has 9 structurally equivalent residues from HIV-1 protease. Unlike the wild-type enzyme, the mutant enzyme hydrolyzes peptides representing the HIV-1 protease polyprotein cleavage sites
S38T/I42D/I44V/M73V/A100L/V104T/R105P/G106V/S107N
-
site-directed mutagenesis leading to the mutant RSV S9 protease, which is active with HIV-1 retropepsin substrates and inhibitable by HIV-1 retropepsin-specific inhibitors in contrast to the wild-type enzyme
V104T
V104T/R105P/G106V/S107N
-
mutant enzyme shows 496% of the activity with PPAVSLAMTMRR as substrate compared to activity of the wild-type enzyme
V225A
-
site-directed mutagenesis of the Gag polyprotein p10 sequence residue leads to accumulation of the mutant protein in the nucleus and reduced virus assembly, overview
V241G
-
site-directed mutagenesis of the p10-capsid protease sequence of Gag polyprotein abolishes the enzyme activity and blocks Rous sarcoma virus replication, detrimental effect, overview
W222A
-
site-directed mutagenesis of the Gag polyprotein p10 sequence residue leads to accumulation of the mutant protein in the nucleus and reduced virus assembly, overview
additional information